Abivax Sa (ABVX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access ABVX Annual Income Statement →
This page allows investors to track Abivax Sa's income statement performance across multiple reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing75.79
Research and Development Expense199.09
Other Operating Expense / -Income0.70
Total operating costs including COS275.58
Operating income / -loss-275.58
Net Interest Expense / -Income0.00
Other loss / -income100.12
Total costs & expenses369.88
Income & Taxes
Income / -loss before income taxes-369.88
Income taxes expenses / -benefit6.55
Income after income taxes-376.43
Income / -loss from continuing operations-376.43
Net income / -loss-376.43
Income / -loss to shareholder-376.43
EBIT-369.88
EBITD-369.88
EBITDA-369.88
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)69.53
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)69.53
4 historic quarters locked

Sign in to unlock the full Abivax Sa income statement history.

About ABVX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.